This suggests that passive immunization with tau antibodies is actually a viable therapeutic goal and that the CSF level of p-tau262/356 or of your microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to observe tau therapeutics in medical trials.A number of colleagues have made the counterargument the sensor mobile reac